These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21302625)

  • 1. Metastatic pancreatic cancer response to treatment with cetuximab and gemcitabine plus capecitabine: a case report and review of the literature.
    Li M; Jiang M; Yan X; Wang F; Luo F
    Tumori; 2010; 96(5):764-7. PubMed ID: 21302625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
    Crane CH; Varadhachary GR; Yordy JS; Staerkel GA; Javle MM; Safran H; Haque W; Hobbs BD; Krishnan S; Fleming JB; Das P; Lee JE; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2011 Aug; 29(22):3037-43. PubMed ID: 21709185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
    Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
    Zafar SF; El-Rayes BF
    Am J Clin Oncol; 2014 Apr; 37(2):194-200. PubMed ID: 22643564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New directions in the management of advanced pancreatic cancer: a review.
    Rocha-Lima CM
    Anticancer Drugs; 2008 Jun; 19(5):435-46. PubMed ID: 18418211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
    Javle M; Yu J; Garrett C; Pande A; Kuvshinoff B; Litwin A; Phelan J; Gibbs J; Iyer R
    Br J Cancer; 2009 Jun; 100(12):1842-5. PubMed ID: 19491904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
    Philip PA; Benedetti J; Corless CL; Wong R; O'Reilly EM; Flynn PJ; Rowland KM; Atkins JN; Mirtsching BC; Rivkin SE; Khorana AA; Goldman B; Fenoglio-Preiser CM; Abbruzzese JL; Blanke CD
    J Clin Oncol; 2010 Aug; 28(22):3605-10. PubMed ID: 20606093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    Rubovszky G; Láng I; Ganofszky E; Horváth Z; Juhos E; Nagy T; Szabó E; Szentirmay Z; Budai B; Hitre E
    Eur J Cancer; 2013 Dec; 49(18):3806-12. PubMed ID: 24007821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Saif MW; Syrigos K; Penney R; Kaley K
    Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
    Xiong HQ; Rosenberg A; LoBuglio A; Schmidt W; Wolff RA; Deutsch J; Needle M; Abbruzzese JL
    J Clin Oncol; 2004 Jul; 22(13):2610-6. PubMed ID: 15226328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
    Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
    Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
    Cascinu S; Berardi R; Labianca R; Siena S; Falcone A; Aitini E; Barni S; Di Costanzo F; Dapretto E; Tonini G; Pierantoni C; Artale S; Rota S; Floriani I; Scartozzi M; Zaniboni A;
    Lancet Oncol; 2008 Jan; 9(1):39-44. PubMed ID: 18077217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Soares HP; Bayraktar S; Blaya M; Lopes G; Merchan J; Macintyre J; Mayo C; Green MR; Silva O; Levi J; Walker G; Rocha-Lima CM
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):839-45. PubMed ID: 24562589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
    Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
    Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
    Stemmler J; Stieber P; Szymala AM; Schalhorn A; Schermuly MM; Wilkowski R; Helmberger T; Lamerz R; Stoffregen C; Niebler K; Garbrecht M; Heinemann V
    Onkologie; 2003 Oct; 26(5):462-7. PubMed ID: 14605463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
    Xenidis N; Chelis L; Amarantidis K; Chamalidou E; Dimopoulos P; Courcoutsakis N; Tentes A; Chiotis A; Prassopoulos P; Kakolyris S
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):477-84. PubMed ID: 21858532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.